Peripheral oxytocin is associated with reduced symptom severity in schizophrenia

Schizophrenia Research

Volumn 124, Issue 1-3, 2010, Pages 13-21

  Rubin, Leah H ^a   Carter, C Sue ^a   Drogos, Lauren ^a   Pournajafi Nazarloo, Hossein ^a   Sweeney, John A ^a   Maki, Pauline M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Estrogen; Menstrual cycle; Oxytocin; Progesterone; Schizophrenia

Indexed keywords

ESTROGEN; OXYTOCIN; PROGESTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLICULAR PHASE; HORMONE DETERMINATION; HUMAN; LUTEAL PHASE; MALE; MENSTRUAL CYCLE; OXYTOCIN BLOOD LEVEL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; CASE-CONTROL STUDIES; ESTROGENS; FEMALE; FOLLICULAR PHASE; HUMANS; LUTEAL PHASE; MALE; MENSTRUAL CYCLE; OXYTOCIN; PREDICTIVE VALUE OF TESTS; PROGESTERONE; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR; TESTOSTERONE; TIME FACTORS; YOUNG ADULT;

EID: 78249235606     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.09.014     Document Type: Article

References (70)

1. Abi-Dargham A., Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003, 9:404-416.
2. Akhondzadeh S., Nejatisafa A.A., Amini H., Mohammadi M.R., Larijani B., Kashani L., Raisi F., Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1007-1012.
3. Akhondzadeh S., Rezaei F., Larijani B., Nejatisafa A.A., Kashani L., Abbasi S.H. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr. Res. 2006, 84:405-410.
4. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch. Intern. Med. 1998, 158:1855-1867.
5. Bakharev V.D., Tikhomirov S.M., Lozhkina T.K. Psychotropic properties of oxytocin. Probl. Endokrinol. (Mosk) 1984, 30:37-41.
6. Beckmann H., Lang R.E., Gattaz W.F. Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 1985, 10:187-191.
7. Bergemann N., Mundt C., Parzer P., Jannakos I., Nagl I., Salbach B., Klinga K., Runnebaum B., Resch F. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr. Res. 2005, 73:357-366.
8. Bergemann N., Mundt C., Parzer P., Pakrasi M., Eckstein-Mannsperger U., Haisch S., Salbach B., Klinga K., Runnebaum B., Resch F. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr. Res. 2005, 74:125-134.
9. Bergemann N., Parzer P., Runnebaum B., Resch F., Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 2007, 37:1427-1436.
10. Brambilla D.J., Matsumoto A.M., Araujo A.B., McKinlay J.B. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J. Clin. Endocrinol. Metab. 2009, 94:907-913.
11. Bujanow W. Hormones in the treatment of psychoses. Br. Med. J. 1972, 4:298.
12. Caldwell H.K., Stephens S.L., Young W.S. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol. Psychiatry 2009, 14:190-196.
13. Carter C.S., Pournajafi-Nazarloo H., Kramer K.M., Ziegler T.E., White-Traut R., Bello D., Schwertz D. Oxytocin: behavioral associations and potential as a salivary biomarker. Ann. NY Acad. Sci. 2007, 1098:312-322.
14. Carter C.S., Grippo A.J., Pournajafi-Nazarloo H., Ruscio M.G., Porges S.W. Oxytocin, vasopressin and sociality. Prog. Brain Res. 2008, 170:331-336.
15. Choi S.H., Kang S.B., Joe S.H. Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom. Med. 2001, 63:822-829.
16. Docherty J.P., Baker R.A., Eudicone J., Mathew S., Marcus R.N., McQuade R.D., Mankoski R. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophr. Res. 2010, 120:199-203.
17. Feifel D., Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berl) 1999, 141:93-98.
18. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010.
19. First M., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P) 1995, New York State Psychiatric Institute, New York.
20. Glovinsky D., Kalogeras K.T., Kirch D.G., Suddath R., Wyatt R.J. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophr. Res. 1994, 11:273-276.
21. Goldman M., Marlow-O'Connor M., Torres I., Carter C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr. Res. 2008, 98:247-255.
22. Gower B.A., Nyman L. Associations among oral estrogen use, free testosterone concentration, and lean body mass among postmenopausal women. J. Clin. Endocrinol. Metab. 2000, 85:4476-4480.
23. Goyal R.O., Sagar R., Ammini A.C., Khurana M.L., Alias A.G. Negative correlation between negative symptoms of schizophrenia and testosterone levels. Ann. NY Acad. Sci. 2004, 1032:291-294.
24. Halbreich U., Kahn L.S. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 2003, 28(Suppl 2):1-16.
25. Hallonquist J.D., Seeman M.V., Lang M., Rector N.A. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol. Psychiatry 1993, 33:207-209.
26. Harris A.H. Menstrually related symptom changes in women with schizophrenia. Schizophr. Res. 1997, 27:93-99.
27. Heinrichs M., von Dawans B., Domes G. Oxytocin, vasopressin, and human social behavior. Front. Neuroendocrinol. 2009, 30:548-557.
28. Howes O.D., Wheeler M.J., Pilowsky L.S., Landau S., Murray R.M., Smith S. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 2007, 68:361-367.
29. Huber T.J., Borsutzky M., Schneider U., Emrich H.M. Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis. Acta Psychiatr. Scand. 2004, 109:269-274.
30. Huber T.J., Tettenborn C., Leifke E., Emrich H.M. Sex hormones in psychotic men. Psychoneuroendocrinology 2005, 30:111-114.
31. Jensen T.K., Andersson A.M., Jorgensen N., Andersen A.G., Carlsen E., Petersen J.H., Skakkebaek N.E. Body mass index in relation to semen quality and reproductive hormones among 1558 Danish men. Fertil. Steril. 2004, 82:863-870.
32. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
33. Keri S., Kiss I., Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc. Neurosci. 2009, 4:287-293.
34. Ko Y.H., Joe S.H., Cho W., Park J.H., Lee J.J., Jung I.K., Kim L., Kim S.H. Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia. Int. J. Psychiatry Clin. Pract. 2006, 10:97-104.
35. Ko Y.H., Jung S.W., Joe S.H., Lee C.H., Jung H.G., Jung I.K., Kim S.H., Lee M.S. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. Psychoneuroendocrinology 2007.
36. Ko Y.H., Lew Y.M., Jung S.W., Joe S.H., Lee C.H., Jung H.G., Lee M.S. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2008, 28:375-383.
37. Konarzewska B., Wolczynski S., Szulc A., Galinska B., Poplawska R., Waszkiewicz N. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009, 34:129-139.
38. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., Fehr E. Oxytocin increases trust in humans. Nature 2005, 435:673-676.
39. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Arch. Womens Ment. Health 2002, 5:99-104.
40. Kulkarni J., de Castella A., Fitzgerald P.B., Gurvich C.T., Bailey M., Bartholomeusz C., Burger H. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 2008, 65:955-960.
41. Landgraf R., Neumann I.D. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front. Neuroendocrinol. 2004, 25:150-176.
42. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 2005, 30:1883-1894.
43. Legros J.J., Gazzotti C., Carvelli T., Franchimont P., Timsit-Berthier M., von Frenckell R., Ansseau M. Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics. Psychoneuroendocrinology 1992, 17:611-617.
44. Lehman A.F., Kreyenbuhl J., Buchanan R.W., Dickerson F.B., Dixon L.B., Goldberg R., Green-Paden L.D., Tenhula W.N., Boerescu D., Tek C., Sandson N., Steinwachs D.M. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr. Bull. 2004, 30:193-217.
45. Liedman R., Hansson S.R., Howe D., Igidbashian S., McLeod A., Russell R.J., Akerlund M. Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects. Gynecol. Endocrinol. 2008, 24:508-513.
46. Linkowski P., Geenen V., Kerkhofs M., Mendlewicz J., Legros J.J. Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur. Arch. Psychiatry Neurol. Sci. 1984, 234:162-165.
47. Loebel A., Siu C., Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004, 9:357-364.
48. Louza M.R., Marques A.P., Elkis H., Bassitt D., Diegoli M., Gattaz W.F. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr. Res. 2004, 66:97-100.
49. Mai J.K., Berger K., Sofroniew M.V. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J. Hirnforsch. 1993, 34:133-154.
50. Marx C.E., Keefe R.S., Buchanan R.W., Hamer R.M., Kilts J.D., Bradford D.W., Strauss J.L., Naylor J.C., Payne V.M., Lieberman J.A., Savitz A.J., Leimone L.A., Dunn L., Porcu P., Morrow A.L., Shampine L.J. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009, 34:1885-1903.
51. Oades R.D., Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 1994, 19:373-385.
52. Parker K.J., Kenna H.A., Zeitzer J.M., Keller J., Blasey C.M., Amico J.A., Schatzberg A.F. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Res. 2010, 178:359-362.
53. Patisaul H.B., Scordalakes E.M., Young L.J., Rissman E.F. Oxytocin, but not oxytocin receptor, is rRegulated by oestrogen receptor beta in the female mouse hypothalamus. J. Neuroendocrinol. 2003, 15:787-793.
54. Purnine D.M., Carey K.B., Maisto S.A., Carey M.P. Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders. J. Nerv. Ment. Dis. 2000, 188:653-661.
55. Rao M.L., Kolsch H. Effects of estrogen on brain development and neuroprotection-implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 2003, 28(Suppl 2):83-96.
56. Riecher-Rossler A., Hafner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr. Scand. Suppl. 2000, 58-62.
57. Riecher-Rossler A., Hafner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophr. Bull. 1994, 20:203-214.
58. Ritsner M.S., Gibel A., Shleifer T., Boguslavsky I., Zayed A., Maayan R., Weizman A., Lerner V., Clin Psychiatry J. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J. Clin. Psychiatry 2010.
59. Rosenfeld A.J., Lieberman J.A., Jarskog L.F. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophr. Bull. 2010.
60. Salonia A., Nappi R.E., Pontillo M., Daverio R., Smeraldi A., Briganti A., Fabbri F., Zanni G., Rigatti P., Montorsi F. Menstrual cycle-related changes in plasma oxytocin are relevant to normal sexual function in healthy women. Horm. Behav. 2005, 47:164-169.
61. Sarnyai Z., Kovacs G.L. Role of oxytocin in the neuroadaptation to drugs of abuse. Psychoneuroendocrinology 1994, 19:85-117.
62. Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Marechal P., Pequeux C., Ansseau M., Legros J.J. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007.
63. Shahrokh, D. K., Zhang, T. Y., Diorio, J., Gratton, A.Meaney, M. J., Oxytocin-dopamine interactions mediate variations in maternal behavior in the rat. Endocrinology. 151, 2276-2286.
64. Theodoridou A., Rowe A.C., Penton-Voak I.S., Rogers P.J. Oxytocin and social perception: oxytocin increases perceived facial trustworthiness and attractiveness. Horm. Behav. 2009, 56:128-132.
65. Thompson K., Sergejew A., Kulkarni J. Estrogen affects cognition in women with psychosis. Psychiatry Res. 2000, 94:201-209.
66. Uvnas-Moberg K., Alster P., Svensson T.H. Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats. Psychopharmacology (Berl) 1992, 109:473-476.
67. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64:663-667.
68. Young L.J., Wang Z., Donaldson R., Rissman E.F. Estrogen receptor alpha is essential for induction of oxytocin receptor by estrogen. NeuroReport 1998, 9:933-936.
69. Zak P.J., Kurzban R., Matzner W.T. Oxytocin is associated with human trustworthiness. Horm. Behav. 2005, 48:522-527.
70. Zumoff B., Strain G.W., Miller L.K., Rosner W., Senie R., Seres D.S., Rosenfeld R.S. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J. Clin. Endocrinol. Metab. 1990, 71:929-931.